ClinicalTrials.gg
Sign In
RecruitingNCT07893561Updated Oct 26, 2026

A Clinical Trial to Evaluate the Effects of Adrenal Adapt on Sleep Quality, Daytime Energy, Stress Resilience, and Cognitive Performance.

An interventional study of Adrenal Adapt in Improves Daytime Energy Levels, Reduces Afternoon Energy Crashes and Midday Fatigue and Improves Overall Sleep Quality and Restorative Sleep, sponsored by Bioligent. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Bioligent · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 26, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a single-group, open-label, uncontrolled clinical trial designed to evaluate the effects of Adrenal Adapt, a commercially available dietary supplement, on sleep quality, daytime energy, stress resilience, and cognitive performance over a 12-week intervention period in 40 healthy adults aged 18-60.

02

Conditions studied

  • Improves Daytime Energy Levels
  • Reduces Afternoon Energy Crashes and Midday Fatigue
  • Improves Overall Sleep Quality and Restorative Sleep
  • Helps People Fall Asleep Faster and Wake Less During the Night
  • Helps People Wake Feeling Refreshed
  • Improves the Body's Resilience and Recovery in Response to Everyday Stress
  • Reduces Perceived Stress and Feelings of Overwhelm
  • Improves Cognitive Performance, Mental Clarity, and Calm Focus Throughout the Day
  • Provides Calm, Steady Energy Without Jitteriness or Overstimulation
  • Reduces Reliance on Caffeine for Daily Energy

Browse trials for

03

In context

Fatigue

2,229 studies on the registry are indexed under Fatigue; 426 are open to participants now.

This study's planned enrollment of 40 is below the median of 54 across 1,757 interventional studies indexed under Fatigue.

Browse Fatigue studies →

Lead sponsor

This is the only study on the registry with Bioligent as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years at the time of enrollment.
  • Experiencing difficulty with at least two of the following: sleep quality (including difficulty falling asleep, nighttime awakenings, or unrefreshing sleep), daytime fatigue or low energy, and/or subjective feelings of elevated stress.
  • Generally healthy - does not live with any uncontrolled chronic disease that would interfere with study participation or confound study outcomes.
  • If currently taking medications, supplements, or herbal remedies targeting sleep, stress, or energy, willing to maintain that routine unchanged for the study duration without introducing any other new products.
  • Willing to take 1 capsule of Adrenal Adapt three times daily with a meal (morning, afternoon, evening) for 12 weeks, not exceeding 3 capsules per day.
  • Willing to avoid excessive caffeine and alcohol for the duration of the study, defined as more than 400mg of caffeine per day, more than 15 alcoholic drinks per week for men and more than 7 alcoholic drinks per week for women.
  • Willing to maintain their current diet, sleep habits, and activity levels for the duration of the trial.
  • Resides in the United States with a valid shipping address.
  • Has consistent access to a smartphone or computer and a reliable internet connection sufficient to complete digital surveys.

Exclusion criteria

Exclusion criteria:

  • Currently pregnant, breastfeeding, or planning to become pregnant at any point during the study period.
  • Currently taking anticoagulant medications (e.g., warfarin, heparin, or direct oral anticoagulants), as specified in the product's known .
  • Known allergy or to any ingredient in Adrenal Adapt (including Hypromellose capsule shell, white rice flour, stearic acid, silicon dioxide, or any of the botanical extracts).
  • Diagnosed with a psychiatric disorder (e.g., major depressive disorder or bipolar disorder) that could confound subjective outcome assessments or interfere with study participation.
  • Diagnosed with a sleep disorder for which pharmacological treatment has been prescribed (e.g., narcolepsy, sleep apnea treated with a CPAP device and prescription medications, insomnia disorder treated with prescription hypnotics).
  • Generated by Citruslabs · 02c23d89-a524-4659-bc54-5792f4592244 Planning to introduce any new prescription medications, supplements, or herbal products targeting sleep, stress, or energy during the study period.
  • History of substance use disorder or currently using recreational drugs that may affect sleep or stress physiology.
  • Planning surgery or a major medical procedure during the 12- week study period.
  • Currently enrolled in or planning to enroll in another research study during the study period.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Adrenal Adapt Arm

    Dietary Supplement: Adrenal Adapt

Interventions

  • Dietary supplementAdrenal Adapt

    All enrolled participants take 1 capsule of Adrenal Adapt three times daily (once in the morning with the first meal of the day, once in the afternoon with the midday meal, and once in the evening with the evening meal), not to exceed 3 capsules per day, for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Overall Sleep Quality

    Change from Baseline in self-reported overall sleep quality (restorative sleep), as assessed by validated sleep quality questionnaire items

    Time frame: Baseline to Week 12

  2. Change in Sleep Onset Latency

    Change from Baseline in self-reported speed of falling asleep, as assessed by validated sleep quality questionnaire items

    Time frame: Baseline to Week 12

  3. Change in Nighttime Awakenings

    Change from Baseline in self-reported frequency of nighttime awakenings (sleep maintenance), as assessed by validated sleep quality questionnaire items

    Time frame: Baseline to Week 12

  4. Change in Subjective Morning Refreshment

    Change from Baseline in self-reported subjective sense of waking refreshed, as assessed by validated sleep quality questionnaire items

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Overall Daytime Energy Levels

    Change from Baseline in self-reported overall daytime energy levels, as assessed by self-reported energy and fatigue questionnaire items

    Time frame: Baseline to Weeks 4, 8, and 12

07

Study locations

1 of 1 sites recruiting
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07893561
Lead sponsor
Bioligent
Collaborators
Citruslabs
Responsible party
Sponsor
First posted
Oct 26, 2026
Start date
Sep 9, 2026
Primary completion
Dec 2, 2026 (estimated)
Completion
Dec 2, 2026 (estimated)
Last update
Oct 26, 2026

Study contacts

Patrick Renner
Contact
hello@citruslabs.com
42424250284

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Fatigue →

Start the discussion